InMed Pharmaceuticals (INM) — AI Analysis & Mentions

INM faces delisting risk after trading under $1.00 for 30 consecutive days. For average investors, this highlights the risk of penny stocks and why Buffett usually avoids them: the downside often outweighs the upside unless there's a truly unique competitive advantage and a strong balance sheet (neither of which is on display here).

After announcing BayMedica's wind-down due to legislative risk, INM is doubling down on its rare-cannabinoid pharmaceuticals pipeline (e.g., INM-901 for Alzheimer's). This strategic sharpening comes with costs, but if successful, could enhance long-term value for shareholders.